• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • Exits

Novalpina fund exits Laboratoire XO to Stanley Capital

  • Rachel Lewis
  • 04 October 2022
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

The managers of Novalpina 1 have made a major step in the winding down of the liquidated fund by selling crown jewel asset Laboratoire XO to Stanley Capital.

The French maker of hypertension treatment Loxen was acquired by Novalpina in November 2020,  just six months before the GP was ousted as the manager of Novalpina 1 by its LPs, as reported.

Consultancy firm Berkeley Research Group (BRG) took over the management of the EUR 1bn fund in July 2021. Laboratoire XO's debt backer, Ares Management, briefly seized control of the company in May in a move that was ultimately overturned by BRG, as reported.

Laboratoire XO

  • DEAL:

    SBO

  • LOCATION:

    Saint Cloud

  • SECTOR:

    Pharmaceuticals

  • TURNOVER:

    EUR 60mm

  • VENDOR:

    Novalpina I

Ares is still the main incumbent lender on the new deal, according to a statement.

Laboratoire XO was considered the most valuable asset in the defunct fund. NSO Group, the controversial spyware maker backed by Novalpine since 2019, has been deemed "valueless" by BRG, and the fund's third asset is a Baltic gambling firm, Olympic Entertainment Group. 

LPs in Novalpina I include Mubadala Capital, pension fund Oregon Investment Council, Alaska's sovereign wealth fund, and local government pension schemes in the UK. 

Buyer Stanley Capital, a mid-market private equity firm that invests in healthcare, technology and resource efficiency, said that the completed deal brings assets under management to USD 440m. 

The firm said it would work with management to strengthen and develop the company through its next phase of growth, adding that there is capital reserved for bolt-on investments.

Company
Headquartered in Saint Cloud, France and founded in 2015, Lab XO specialises in mature market authorisations to sell and market drugs across various therapeutic areas such as pain, central nervous system, cardiology, oral care, and women’s health. With a turnover of EUR 60m, 26 brands, and a distribution network of more than 45 countries (US, Europe, the Maghreb, and the Francophone world). 

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Exits
  • Healthcare
  • LPs
  • GPs
  • healthcare
  • France

More on Exits

Influencers and social media
Inflexion sells The Goat Agency to trade, nets 80% IRR

GP sells minority stake in UK-based social media marketing agency after two year investment period

  • Exits
  • 22 March 2023
Auction houses and open sales processes
Lenders sway fate of auctions in volatile LBO market

Vendors increasingly sounding out lenders before bidders to navigate uncertain M&A landscape

  • Exits
  • 20 March 2023
Wheelchairs and other mobility products
Nordic picks Jefferies for upcoming Sunrise Medical auction

German wheelchair specialist was acquired in 2015 and moved to a continuation fund in 2018

  • Exits
  • 17 March 2023
Albert Farrant of Inspirit
GP Profile: Inspirit anticipates carve-outs uptick with fundraising on the horizon by year-end

Complex carve-outs specialist could raise around GBP 75m for its second fund with debut vehicle around 70% deployed

  • Exits
  • 17 March 2023

Latest News

Andy Gregory of BGF
  • GPs
GP Profile: BGF to deploy GBP 500m-plus per year for minority growth deals with entrepreneurs

UK and Ireland-based growth investor remains committed to filling a market gap for founders who want flexibility and control

  • 23 March 2023
Credit Suisse Headquarters building and UBS building to the left Paradeplatz Bahnhofstrasse Zurich
  • Industry
European sponsors sidestep panic, concede gloom over bank woes

Fallout from Credit Suisse collapse adds to slew of macroeconomic challenges for PE dealmaking and fundraising

  • 22 March 2023
Influencers and social media
  • Exits
Inflexion sells The Goat Agency to trade, nets 80% IRR

GP sells minority stake in UK-based social media marketing agency after two year investment period

  • 22 March 2023
Online learning courses
  • Buyouts
Synova kicks off new fund deployment with Learnlight acquisition

Investment in Spanish edtech platform is the first from GBP 875m vehicle raised in three months last year

  • 22 March 2023
Back to Top

Most read

Andy Gregory of BGF
GP Profile: BGF to deploy GBP 500m-plus per year for minority growth deals with entrepreneurs
Credit Suisse Headquarters building and UBS building to the left Paradeplatz Bahnhofstrasse Zurich
European sponsors sidestep panic, concede gloom over bank woes
Influencers and social media
Inflexion sells The Goat Agency to trade, nets 80% IRR
Online learning courses
Synova kicks off new fund deployment with Learnlight acquisition
Marek Moravec of Nation 1
Nation 1 launches new early-stage, EUR 35m-EUR 40m fund
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013